A Positively Charged Cluster in the Epidermal Growth Factor-like Domain of Factor VII-activating Protease (FSAP) is Essential for Polyanion Binding

Overview

Journal Biochem J

Specialty Biochemistry

Date 2005 Dec 8

PMID 16332249

Citations 13

Authors

Boran Altincicek

Aya Shibamiya

Heidi Trusheim

Eleni Tzima

Michael Niepmann

Dietmar Linder

Klaus T Preissner

Sandip M Kanse

Affiliations

Soon will be listed here.

Abstract

FSAP (Factor VII-activating protease) is a novel plasma-derived serine protease that regulates haemostasis as well as vascular cell proliferation. FSAP undergoes autoactivation in the presence of polyanionic macromolecules such as heparin and RNA. Competition experiments suggest that RNA and heparin bind to the same or overlapping interaction sites. A proteolysis approach, where FSAP was hydrolysed into smaller fragments, was used to identify the polyanion-binding site. The EGF (epidermal growth factor)-like domains EGF2 and EGF3 of FSAP are the major interaction domains for RNA. The amino acids Arg170, Arg171, Ser172 and Lys173 within the EGF3 domain were essential for this binding. This is also the region with the highest positive net charge in the protein and is most probably located in an exposed loop. It is also highly conserved across five species. Disruption of disulphide bridges led to the loss of RNA and heparin binding, indicating that the three-dimensional structure of the EGF3 domain is essential for binding to negatively charged heparin or RNA. The identification of polyanion-binding sites will help to define the role of FSAP in the vasculature.

Citing Articles

Targeted Therapy with Cisplatin-Loaded Calcium Citrate Nanoparticles Conjugated with Epidermal Growth Factor for Lung Cancer Treatment.

Oopkaew L, Injongkol Y, Rimsueb N, Mahalapbutr P, Choowongkomon K, Hadsadee S ACS Omega. 2024; 9(24):25668-25677.

PMID: 38911765 PMC: 11191089. DOI: 10.1021/acsomega.3c08969.

Multifunctional Cationic Hyperbranched Polyaminoglycosides that Target Multiple Mediators for Severe Abdominal Trauma Management.

Xiao Y, Fang H, Zhu Y, Zhou J, Dai Z, Wang H Adv Sci (Weinh). 2023; 11(1):e2305273.

PMID: 37997512 PMC: 10767409. DOI: 10.1002/advs.202305273.

Factor VII Activating Protease (FSAP) and Its Importance in Hemostasis-Part I: FSAP Structure, Synthesis and Activity Regulation: A Narrative Review.

Kwiatkowska I, Zekanowska E, Lattanzi S, Alexandre A, Kister-Kowalska A, Slomka A Int J Mol Sci. 2023; 24(6).

PMID: 36982544 PMC: 10052181. DOI: 10.3390/ijms24065473.

Identification of a Phage Display-Derived Peptide Interacting with the N-Terminal Region of Factor VII Activating Protease (FSAP) Enables Characterization of Zymogen Activation.

Berge-Seidl S, Nielsen N, Rodriguez Alfonso A, Etscheid M, Kandanur S, Haug B ACS Chem Biol. 2022; 17(9):2631-2642.

PMID: 36070465 PMC: 9486805. DOI: 10.1021/acschembio.2c00538.

HABP2 is a Novel Regulator of Hyaluronan-Mediated Human Lung Cancer Progression.

Mirzapoiazova T, Mambetsariev N, Lennon F, Mambetsariev B, Berlind J, Salgia R Front Oncol. 2015; 5:164.

PMID: 26258071 PMC: 4508840. DOI: 10.3389/fonc.2015.00164.

References

Kannemeier C, Al-Fakhri N, Preissner K, Kanse S . Factor VII-activating protease (FSAP) inhibits growth factor-mediated cell proliferation and migration of vascular smooth muscle cells. FASEB J. 2004; 18(6):728-30. DOI: 10.1096/fj.03-0898fje. View

Etscheid M, Beer N, Kress J, Seitz R, Dodt J . Inhibition of bFGF/EGF-dependent endothelial cell proliferation by the hyaluronan-binding protease from human plasma. Eur J Cell Biol. 2004; 82(12):597-604. DOI: 10.1078/0171-9335-00349. View

Brockway W, Castellino F . Measurement of the binding of antifibrinolytic amino acids to various plasminogens. Arch Biochem Biophys. 1972; 151(1):194-9. DOI: 10.1016/0003-9861(72)90488-2. View

Hojima Y, Cochrane C, Wiggins R, Austen K, Stevens R . In vitro activation of the contact (Hageman factor) system of plasma by heparin and chondroitin sulfate E. Blood. 1984; 63(6):1453-9. View

Chen X, Sadlock J, Schon E . RNA-binding patterns in total human tissue proteins: analysis by northwestern blotting. Biochem Biophys Res Commun. 1993; 191(1):18-25. DOI: 10.1006/bbrc.1993.1178. View

Pixley R, Colman R . Factor XII: Hageman factor. Methods Enzymol. 1993; 222:51-65. DOI: 10.1016/0076-6879(93)22007-3. View

Tan R, Frankel A . Structural variety of arginine-rich RNA-binding peptides. Proc Natl Acad Sci U S A. 1995; 92(12):5282-6. PMC: 41678. DOI: 10.1073/pnas.92.12.5282. View

Smith B, Downing A, Driscoll P, Dudgeon T, Campbell I . The solution structure and backbone dynamics of the fibronectin type I and epidermal growth factor-like pair of modules of tissue-type plasminogen activator. Structure. 1995; 3(8):823-33. DOI: 10.1016/s0969-2126(01)00217-9. View

Citarella F, Ravon D, Pascucci B, Felici A, Fantoni A, Hack C . Structure/function analysis of human factor XII using recombinant deletion mutants. Evidence for an additional region involved in the binding to negatively charged surfaces. Eur J Biochem. 1996; 238(1):240-9. DOI: 10.1111/j.1432-1033.1996.0240q.x. View

10.

Choi-Miura N, Tobe T, Sumiya J, Nakano Y, Sano Y, Mazda T . Purification and characterization of a novel hyaluronan-binding protein (PHBP) from human plasma: it has three EGF, a kringle and a serine protease domain, similar to hepatocyte growth factor activator. J Biochem. 1996; 119(6):1157-65. DOI: 10.1093/oxfordjournals.jbchem.a021362. View

11.

Colman R, Schmaier A . Contact system: a vascular biology modulator with anticoagulant, profibrinolytic, antiadhesive, and proinflammatory attributes. Blood. 1997; 90(10):3819-43. View

12.

Sumiya J, Asakawa S, Tobe T, Hashimoto K, Saguchi K, Choi-Miura N . Isolation and characterization of the plasma hyaluronan-binding protein (PHBP) gene (HABP2). J Biochem. 1998; 122(5):983-90. DOI: 10.1093/oxfordjournals.jbchem.a021861. View

13.

Guex N, Peitsch M . SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. Electrophoresis. 1998; 18(15):2714-23. DOI: 10.1002/elps.1150181505. View

14.

Braat E, Dooijewaard G, Rijken D . Fibrinolytic properties of activated FXII. Eur J Biochem. 1999; 263(3):904-11. DOI: 10.1046/j.1432-1327.1999.00593.x. View

15.

Nakazawa F, Kannemeier C, Shibamiya A, Song Y, Tzima E, Schubert U . Extracellular RNA is a natural cofactor for the (auto-)activation of Factor VII-activating protease (FSAP). Biochem J. 2005; 385(Pt 3):831-8. PMC: 1134760. DOI: 10.1042/BJ20041021. View

16.

Hoppe B, Tolou F, Radtke H, Kiesewetter H, Dorner T, Salama A . Marburg I polymorphism of factor VII-activating protease is associated with idiopathic venous thromboembolism. Blood. 2004; 105(4):1549-51. DOI: 10.1182/blood-2004-08-3328. View

17.

Romisch J, Feussner A, Vermohlen S, Stohr H . A protease isolated from human plasma activating factor VII independent of tissue factor. Blood Coagul Fibrinolysis. 2000; 10(8):471-9. View

18.

Citarella F, Te Velthuis H, Helmer-Citterich M, Hack C . Identification of a putative binding site for negatively charged surfaces in the fibronectin type II domain of human factor XII--an immunochemical and homology modeling approach. Thromb Haemost. 2001; 84(6):1057-65. View

19.

Etscheid M, Hunfeld A, Konig H, Seitz R, Dodt J . Activation of proPHBSP, the zymogen of a plasma hyaluronan binding serine protease, by an intermolecular autocatalytic mechanism. Biol Chem. 2001; 381(12):1223-31. DOI: 10.1515/BC.2000.150. View

20.

Choi-Miura N, Yoda M, Saito K, Takahashi K, Tomita M . Identification of the substrates for plasma hyaluronan binding protein. Biol Pharm Bull. 2001; 24(2):140-3. DOI: 10.1248/bpb.24.140. View